


| Revenue | $10 - $100 million See Exact Annual Revenue |
|---|---|
| Employees | N/AExact Company Size |
| Primary Industry | 5417 Scientific Research & Development Services |
| Additional NAICS Codes | 325412 Pharmaceutical Preparation Manufacturing |
| Address | 1 World Trade Ctr Fl 22 New York, NY 10007 |
| Axsome Therapeutics | Revenue Est. ($ Million) | Growth Rate (%) | # Employees |
|---|---|---|---|
| 2025 | $10 - $100 million Details in Premium Report | ||
| 2024 | |||
| 2023 | |||
| 2021 | |||
| 2020 | |||
| 2019 | |||
|
1-Year Growth Rate: 3-Year Growth Rate (CAGR): | ![]() |
| Axsome Therapeutics P&L | $ Millions |
|---|---|
| Revenue (Sales) | ![]() |
| Cost of Goods Sold | |
| Gross Profit | |
Operating Expenses | |
| Advertising | |
| Salaries and wages | |
| Other Operating Expenses | |
| Total Operating Expenses | |
| Operating Income | |
| EBITDA | |
| EBIT (Earnings Before Interest and Taxes) | |
| Net Profit | |
| Trademark | Date |
|---|---|
| EVOS Downloadable cloud-based software for the purpose of tracking, managing and storing information related to medications and medication compliance, patient health, wellness and symptoms, and patient diseases and disorders; Downloadable software in the nature of a mobile application for the purpose of tracking, managing and storing information related to medications and medication compliance, patient health, wellness and symptoms, and patient diseases and disorders | 11/30/2023 |
| MYVELO Prescription medicines for the treatment of Fibromyalgia | 07/27/2023 |
| AXSOME THERAPEUTICS house mark for a full line of medicated and pharmaceutical preparations for use in connection with humans, namely, antibiotics, antifungals preparations, antivirals, and for treatment of cardiovascular, dermatological, respiratory, central nervous system, gastro-intestinal diseases, autoimmune, metabolic, endocrine, musculo-skeletal, genitourinary, tissue and organ, ocular, ophthalmological, immune system, pain, kidney, urological, and bone diseases and disorders and for the treatment of fibromyalgia, smoking cessation, narcolepsy, excessive daytime sleepiness, alzheimer's disease agitation, migraine, depression, diabetes, hypertension, skin disorders, allergies, asthma, obesity, and hair loss | 07/26/2023 |
| Company | Headquarters | Revenue ($ MM) |
|---|---|---|
| LEIDOS | Denver, CO | 100 |
| NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA | Albuquerque, NM | 30 |
| INC RESEARCH | Raleigh, NC | 27 |
| RESEARCH FOUNDATION FOR STATE UNIVERSITY OF NEW YORK | Albany, NY | 17 |
| FLUOR MARINE PROPULSION | West Mifflin, PA | 15 |
| SYNEOS HEALTH | Raleigh, NC | 13 |
| ILLUMINA | San Diego, CA | 12 |
| UT-BATTELLE | Oak Ridge, TN | 11 |
| PRA HOLDINGS | Raleigh, NC | 11 |
| Company | Headquarters | Revenue ($ MM) |
|---|---|---|
| ITI | New York, NY | 100 |
| STEMLINE THERAPEUTICS | New York, NY | 67 |
| TG THERAPEUTICS | New York, NY | 58 |
| POPULATION COUNCIL | New York, NY | 53 |
| NEW YORK GENOME CENTER | New York, NY | 33 |
| OXFORD NANOPORE TECHNOLOGIES | New York, NY | 23 |
| Company | Revenue ($ MM) |
|---|---|
![]() | |